Indian pharma stocks fall after Trump's new drug tariffs

Core Viewpoint - Indian pharmaceutical stocks experienced a decline of 2.6% following the announcement of a 100% tariff on branded and patented drugs by U.S. President Donald Trump, which is set to take effect on October 1 [1] Industry Impact - The announcement of the tariff is expected to significantly impact the Indian pharmaceutical sector, which relies heavily on exports to the U.S. market [1] - The 100% tariff could lead to increased costs for Indian pharmaceutical companies, potentially affecting their profit margins and competitiveness in the U.S. [1]